Duality Biologics’ DB-1303 on Track for Breakthrough Designation for HER2+ Endometrial Cancer
The Center for Drug Evaluation (CDE) website has indicated that DB-1303, a HER2 targeted antibody...
Company
Apeloa Pharmaceutical and ZhenGe Biotech Join Forces to Create Comprehensive ADC Platform
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic...
ClouDr Inks Deal with CR Sanjiu to Boost Hospital Sales of Cardiovascular Medicine
Hangzhou Kang Ming Information Technology Co., Ltd, (HKG: 9955) trading under the moniker “ClouDr”, has...
Lundbeck A/S Posts 8.2% YOY Revenue Growth in 2023 with Strong Performance Across Key Therapies
Danish pharmaceutical company Lundbeck A/S (FRA: LDBB) has announced its financial results for 2023, highlighting...
Formosa Pharmaceuticals Secures FDA Nod for New Steroidal Eye Drug, Set to Launch via Eyenovia
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has received approval from the US Food and Drug Administration...
MGI Tech Lands Eurofins Genomics Deal for T20 Ultra-High Throughput Sequencer in Europe
MGI Tech (SHA: 688114), a China-based sequencing company, has announced a significant collaboration with Eurofins...
Bayer Posts 1.2% YOY Sales Decline in 2023 with Pharmaceuticals and Consumer Health Segment Updates
Germany’s Bayer (ETR: BAYN) has released its financial results for 2023, marking a year of...
Novo Nordisk’s Ozempic Meets Phase III Endpoints in Type 2 Diabetes and Chronic Kidney Disease Study
Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, has this week published results from a...
Sandoz Achieves FDA Milestone with Approval of First US Denosumab Biosimilars
The US Food and Drug Administration (FDA) has granted Sandoz (SWX: SDZ), a Switzerland-based pharmaceutical...
Hybio Pharmaceutical Gets FDA Nod for Liraglutide Raw Materials with DMF Adequacy Letter
Hybio Pharmaceutical Co., Ltd (SHE: 300199), a China-based pharmaceutical company, has announced that it has...
Shanghai RAAS Receives NMPA Approval to Initiate Clinical Trial for Hemophilia Preventive Treatment
Shanghai RAAS (SHE: 002252), a biopharmaceutical company based in China, has announced that it has...
Bio-Thera Solutions Receives NMPA Approval for Three Cancer Treatments Including a Novel ADC
Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, has received separate clinical trial approvals...
EMA Reviews Datopotamab Deruxtecan Filings from AstraZeneca and Daiichi Sankyo for Oncology Indications
The European Medicines Agency (EMA) has accepted for review two oncology filings for the antibody-drug...
Pfizer’s Cibinqo Secures NMPA Approval for Expanded Use in Atopic Dermatitis
The National Medical Products Administration (NMPA) has released drug approval certificate delivery information that points...
Novartis Gene Therapy Zolgensma Shows Continued Benefits in Broader SMA Patient Group
Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented Phase III data this week, demonstrating that...
Bitterroot Bio and Biotheus Inc. Join Forces to Develop Therapies for Cardiovascular Diseases
California-based biotechnology company Bitterroot Bio has announced the signing of a multi-year research collaboration agreement...
Luye Pharma Initiates Phase III Clinical Trial for Irinotecan Liposome Injection in Small-Cell Lung Cancer
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the enrollment of the...
Henlius Biotech Forecasts First-Ever Profit in 2023 Driven by Sales Growth and Efficient Management
Shanghai Henlius Biotech Inc., (HKG: 2696), a China-based biopharmaceutical company, has released a positive profit...
Nuance Pharma Wins Arbitration, Rescinds Licensing Deal with Antibe Therapeutics
Nuance Pharma, a China-based pharmaceutical company, has received a favorable arbitration verdict from a Singapore...
Aosaikang’s Marketing Approval Filing for Delafloxacin Accepted by China’s NMPA
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has announced that the...